_page-0001.jpg)
What's the article about?
- It talks about the serious issue of identical and similar trade names for drugs in India, leading to potential medication errors and endangering patient safety.
Relevance:
- GS2: Issues Relating to Development and Management of Social Sector/Services relating to Health, Education, Human Resources
Context:
- The use of identical trade names for drugs with different active ingredients poses a significant risk to patient safety. This practice has been a longstanding issue in the pharmaceutical industry, leading to potential confusion and medication errors, as exemplified by the case of 'Linamac' being used for drugs treating entirely different conditions
Analysis:
- Main Issues:
- Identical Names: Different drugs with entirely different active ingredients and uses share the same brand name, like “Linamac” for both cancer and diabetes medication.
- Similar Names: Phonetically or visually similar names further aggravate the problem, like “Medzole” for four different drugs and “Medpol/Medrol/Metrozole” for entirely unrelated medications.
- Repurposed Names: Companies exploit successful brand names, like “i-Pill” for both emergency and daily contraceptive pills, leading to potential misuse.
- Widespread Illiteracy and Unregulated Pharmacies: Lack of English proficiency and poorly regulated pharmacies without trained personnel exacerbate the risk of dispensing errors.
- Consequences:
- Prescription Errors: Confusion between drugs can lead to incorrect medication, with potentially fatal outcomes.
- Unwanted Pregnancies: Misuse of contraceptives due to similar names can cause unintended pregnancies.
- Lack of Data and Reform: India's lack of data on prescription errors hinders the recognition and rectification of the problem.
- Regulatory Apathy: Despite recommendations from the Supreme Court and Parliament, the Ministry of Health has failed to implement measures to prevent confusingly similar drug names.
- Possible Solutions:
- Centralized Database: Create a comprehensive database of all pharmaceutical brand names in India.
- Dedicated Regulatory Body: Establish a specialized division within the drug regulatory authority to scrutinize drug names for potential confusion.
- International Best Practices: Implement mechanisms similar to those in the US and Europe for thorough drug name evaluation.
- Pharmacist Training: Ensure all pharmacies are staffed by trained and licensed professionals.
Way Forward:
- India's current system of duplicate and similar drug names is a ticking time bomb. Comprehensive reforms, including data collection and robust name vetting, are crucial to prevent potentially fatal medication errors and protect the health of millions.
